Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Detrothyronine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 14/20 | 0.97 |
| ▸ | THRA known ✓ | P10827 | 10/20 | 0.97 |
| ▸ | LMNA | P02545 | 6/20 | 0.97 |
| ▸ | MEN1 | O00255 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.97 |
| ▸ | PCNA | P12004 | 4/20 | 0.97 |
| ▸ | PPARG | P37231 | 4/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.97 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.97 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | GABRP | O00591 | 1/20 | 0.97 |
| ▸ | GABRD | O14764 | 1/20 | 0.97 |
| ▸ | F2 | P00734 | 1/20 | 0.97 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.97 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.97 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.97 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Liothyronine SCHEMBL387012 | 1.00 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL29651848 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL3287278 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL8301 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Rathyronine SCHEMBL123365 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL29383803 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL8300 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL29390909 | 0.99 | THRB (1.00) | THRBTHRALMNAMEN1KMT2A | |
| Detrothyronine SCHEMBL4608153 | 0.97 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A | |
| Liothyronine SCHEMBL2679283 | 0.97 | THRB (0.97) | THRBTHRALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059682-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023190745-A1 | CONJUNCTIVAL EPITHELIUM MARKER AND USE FOR SAME | 国立大学法人大阪大学 | 2023-10-05 | — | — | WO | disclosed |
| EP-4017875-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3840755-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021041237-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885LMNA 2156/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885LMNA 2210/4885 |
| US-20240059682-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885LMNA 2070/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885LMNA 2210/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885LMNA 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.